WSGR logoWSGR logo
WSGR logo
  • Experience
  • People
  • Insights
  • About Us
  • Careers

  • Practice Areas
  • Industries

  • Corporate
  • Intellectual Property
  • Litigation
  • Patents and Innovations
  • Regulatory
  • Technology Transactions

  • Capital Markets
  • Corporate Governance
  • Corporate Life Sciences
  • Derivatives
  • Emerging Companies and Venture Capital
  • Employee Benefits and Compensation
  • Energy and Climate Solutions
  • Executive Advisory Program
  • Finance and Structured Finance
  • Fund Formation
  • Greater China
  • Mergers & Acquisitions
  • Private Equity
  • Public Company Representation
  • Real Estate
  • Restructuring
  • Shareholder Engagement and Activism
  • Tax
  • U.S. Expansion

  • Special Purpose Acquisition Companies (SPACs)

  • Environmental, Social, and Governance

  • AI and Data Center Infrastructure
  • Energy Regulation and Competition
  • Project Development and M&A
  • Project Finance and Tax Credit Transactions
  • Sustainability and Decarbonization
  • Transportation Electrification

  • U.S. Expansion Library and Resources

  • Post-Grant Review
  • Trademark and Advertising

  • Antitrust Litigation
  • Arbitration
  • Board and Internal Investigations
  • Class Action Litigation
  • Commercial Litigation
  • Consumer Litigation
  • Corporate Governance Litigation
  • Employment Litigation
  • Government Investigations
  • Internet Strategy and Litigation
  • Patent Litigation
  • Securities Litigation
  • State Attorneys General
  • Supreme Court and Appellate Practice
  • Trade Secret Litigation
  • Trademark and Copyright Litigation
  • Trial
  • White Collar Crime

  • Advertising, Promotions, and Marketing
  • Antitrust and Competition
  • Committee on Foreign Investment in the U.S. (CFIUS)
  • Communications
  • Data, Privacy, and Cybersecurity
  • Export Control and Sanctions
  • FCPA and Anti-Corruption
  • Federal Trade Commission
  • Fintech and Financial Services
  • Government Contracts
  • Healthcare and FDA Regulatory
  • National Security and Trade
  • Payments
  • State Attorneys General
  • Strategic Risk and Crisis Management
  • Tariffs, Customs, and Import Compliance

  • Antitrust and Intellectual Property
  • Antitrust Civil Enforcement
  • Antitrust Compliance and Business Strategy
  • Antitrust Criminal Enforcement
  • Antitrust Litigation
  • Antitrust Merger Clearance
  • European Competition Law
  • Third-Party Merger and Non-Merger Antitrust Representation

  • FDA Regulatory and Compliance

  • Anti-Money Laundering
  • Foreign Ownership, Control, or Influence (FOCI)
  • Team Telecom

  • AI in Healthcare
  • Animal Health
  • Artificial Intelligence and Machine Learning
  • Aviation
  • Biotech
  • Blockchain and Cryptocurrency
  • Clean Energy
  • Climate and Clean Technologies
  • Communications and Networking
  • Consumer Products and Services
  • Data Storage and Cloud
  • Defense Tech
  • Diagnostics, Life Science Tools, and Deep Tech
  • Digital Health
  • Digital Media and Entertainment
  • Electronic Gaming
  • Fintech and Financial Services
  • FoodTech and AgTech
  • Global Generics
  • Internet
  • Life Sciences
  • Medical Devices
  • Mobile Devices
  • Mobility
  • NewSpace
  • Quantum Computing
  • Semiconductors
  • Software

  • Offices
  • Country Desks
  • Events
  • Community
  • Our Diversity
  • Sustainability
  • Our Values
  • Board of Directors
  • Management Team

  • Austin
  • Boston
  • Boulder
  • Brussels
  • Century City
  • Hong Kong
  • London
  • Los Angeles
  • New York
  • Palo Alto
  • Salt Lake City
  • San Diego
  • San Francisco
  • Seattle
  • Shanghai
  • Washington, D.C.
  • Wilmington, DE

  • Law Students
  • Judicial Clerks
  • Experienced Attorneys
  • Patent Agents
  • Business Professionals
  • Alternative Legal Careers
  • Contact Recruiting
Hee Min Noh
Associate
Patents and Innovations
San Diego
hnoh@wsgr.com

D858-350-2310

Download vCard
Open PDF

Hee Min Noh is an associate in the San Diego office of Wilson Sonsini Goodrich & Rosati, where she is a member of the firm’s patents and innovations group. Hee Min advises biotechnology and pharmaceutical companies focusing on patent prosecution and intellectual property counseling in the areas of therapeutic antibodies, antibody drug conjugates, antibody oligonucleotide conjugates, RNA therapeutics, and cell therapy. Her expertise includes patent prosecution, global patent portfolio development and management, due diligence, and patentability and freedom-to-operate analyses. She also assists clients with IP matters in various transactions, such as financings, M&A, licenses, and public offerings.

Prior to joining the firm, Hee Min worked as a Korean patent attorney at IP law firms in South Korea. She prosecuted domestic and foreign patent applications and advised clients on patentability, invalidity, infringement, and freedom-to-operate issues. In addition, she litigated patents before the Korean Patent Court and prepared a technical analysis in a patent infringement case before the Supreme Court of Korea.

Hee Min is fluent in Korean and Japanese.

Experience

Hee Min Noh is an associate in the San Diego office of Wilson Sonsini Goodrich & Rosati, where she is a member of the firm’s patents and innovations group. Hee Min advises biotechnology and pharmaceutical companies focusing on patent prosecution and intellectual property counseling in the areas of therapeutic antibodies, antibody drug conjugates, antibody oligonucleotide conjugates, RNA therapeutics, and cell therapy. Her expertise includes patent prosecution, global patent portfolio development and management, due diligence, and patentability and freedom-to-operate analyses. She also assists clients with IP matters in various transactions, such as financings, M&A, licenses, and public offerings.

Prior to joining the firm, Hee Min worked as a Korean patent attorney at IP law firms in South Korea. She prosecuted domestic and foreign patent applications and advised clients on patentability, invalidity, infringement, and freedom-to-operate issues. In addition, she litigated patents before the Korean Patent Court and prepared a technical analysis in a patent infringement case before the Supreme Court of Korea.

Hee Min is fluent in Korean and Japanese.

Education
  • J.D., University of California College of the Law, San Francisco
  • B.S., Biochemistry, Yonsei University
Admissions
  • State Bar of California
  • U.S. Patent and Trademark Office
Credentials
Education
  • J.D., University of California College of the Law, San Francisco
  • B.S., Biochemistry, Yonsei University
Admissions
  • State Bar of California
  • U.S. Patent and Trademark Office

Biological Sciences and Biotechnology

  • Antibody
  • Antigen presentation
  • Biochemistry
  • Bioconjugation
  • Biologics
  • Cancer biology
  • Cancer therapeutics
  • CAR-T cells
  • Cell biology
  • Cell therapy
  • Cellular immunology
  • Immuno-oncology
  • Immunobiology
  • Immunology
  • MicroRNA (miRNA) research

Therapeutics and Drug Discovery

  • Antimicrobial agents
  • Drug conjugates
  • Drug conjugates based drug discovery
  • Drug delivery
  • Gene therapy
  • Immunotherapy targets
  • Peptide therapeutics
  • RNA interference (RNAi)

Diagnostics and Medical Devices

  • Diagnostics
  • Medical devices
  • miRNA detection
Technical Fluency

Biological Sciences and Biotechnology

  • Antibody
  • Antigen presentation
  • Biochemistry
  • Bioconjugation
  • Biologics
  • Cancer biology
  • Cancer therapeutics
  • CAR-T cells
  • Cell biology
  • Cell therapy
  • Cellular immunology
  • Immuno-oncology
  • Immunobiology
  • Immunology
  • MicroRNA (miRNA) research

Therapeutics and Drug Discovery

  • Antimicrobial agents
  • Drug conjugates
  • Drug conjugates based drug discovery
  • Drug delivery
  • Gene therapy
  • Immunotherapy targets
  • Peptide therapeutics
  • RNA interference (RNAi)

Diagnostics and Medical Devices

  • Diagnostics
  • Medical devices
  • miRNA detection
Focus Areas
  • Biotech
  • Life Sciences
  • Medical Devices
  • Patents and Innovations
Recent Insights
Client Highlights
Wilson Sonsini Advises Atrium Therapeutics on Patent Matters Related to $50 Million Private Placement
On October 8, 2026, Atrium Therapeutics, a biopharmaceutical company advancing precision cardiology by developing RNA therapeutics targeted to the heart, announced that it has entered into a securities purchase agreement with a group of leading institutional investors for a private placement financing. The financing is expected to result in aggregate gross proceeds of approximately $50 million, before deducting placement agent fees and other offering expenses. Wilson Sonsini Goodrich & Rosati advised Atrium Therapeutics on patent matters related to the transaction.
Learn More
Client Highlights
Wilson Sonsini Advises Avidity Biosciences on Patent Matters Related to $600 Million Upsized Public Offering
On September 12, 2025, Avidity Biosciences, Inc., a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), announced the pricing of its upsized underwritten public offering of 15,000,000 shares of its common stock at a price to the public of $40.00 per share. All of the shares to be sold in the offering are to be sold by Avidity. The gross proceeds to Avidity from the offering, before deducting the underwriting discounts and commissions and other offering expenses, are expected to be $600 million. Wilson Sonsini Goodrich & Rosati is advising Avidity Biosciences on patent matters related to the transaction.
Learn More
View All
  • people
  • insights
  • about us
  • careers
  • Binder
  • Alumni
  • Mailing List Signup
  • Client FTP Portal
  • Cookie Settings
  • Privacy Policy
  • Terms of Use
  • Accessibility
WSGR logo
Twitter
LinkedIn
Facebook
Instagram
Youtube
Copyright © 2026 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.